Martin Fitchet
Basel
Summary
Physician and global life sciences leader with a track record of creating value and delivering impact in Pharmaceuticals R&D (cardiovascular & metabolism), MedTech R&D and Global Public Health. Passionate advocate of the power of innovation to significantly improve patient outcomes and drive positive impact in patients suffering from serious diseases.
Overview
32
32
years of professional experience
Work History
Global Head, Global Public Health (GPH)
Johnson & Johnson
02.2020 - 04.2023
- Led J&J Global Public Health (GPH), a fully-dedicated organization combining research and development, global access strategies and programs, and regional (Africa and Asia) operations
- Mission to maximize impact and improve healthcare for the world's most vulnerable and underserved populations
- Core to the model was innovation of a portfolio of novel vaccines and medicines for LIMC high burden diseases and ensuring affordable and sustainable access
- Priority disease areas included COVID-19, Ebola, TB, Neglected Tropical Diseases and Mental Health, as well as surgical solutions for long bone fracture and obstetric fistula.
Global Therapeutic Area Head - Pulmonary Hypertension R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
10.2017 - 02.2020
- With the acquisition of Actelion by J&J, assumed role of Global Therapeutic Area Head for Pulmonary Hypertension (PH), responsible for Actelion's R&D strategy and execution across its portfolio of assets in PH
- Global leadership for novel development programs for the portfolio of endothelial & prostacyclin receptor antagonists
- Established of a new PH Disease Area Stronghold driving novel preclinical programs, scientific L&A assessment as well as diagnostics and data sciences
- Supported the successful integration of Actelion into Janssen R&D.
Global Head, Research & Development - Medical Devices & Orthopedics
Johnson & Johnson MedTech
07.2014 - 10.2017
- Led all Research and Development for the company's Medical Devices Sector
- Led a global team of biomedical engineers, physicians, scientists and regulatory professionals developing novel technologies and devices to advance surgical care across general surgery, wound closure, cardiovascular ablation, neurovascular interventions and orthopedics
- Created a global unified organization across franchises, introduced portfolio management processes and built cross-franchise centers of excellence in regulatory, clinical development, medical affairs and preclinical sciences.
Chief Operating Officer - Pharmaceuticals R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
05.2011 - 06.2014
- Reporting to Global Head of Pharmaceutical R&D, created an integrated global organization of >4500 responsible for Development Operations
- Included Clinical Operations, Biostatistics and Programming, Integrated Data Services, Advanced Modelling & Simulation, Data Management, Medical Writing, Drug Safety Sciences (toxicology), Quality Assurance & Management & Clinical Pharmacology
- Created an integrated Quantitative Sciences group to drive more efficient development decision making
- Included novel and adaptive study designs and advanced data analysis and simulation
- Improved development efficiency, via improved and faster decision making, also delivering $350MM year-on-year opex savings, allowing reinvestment into R&D innovation.
Global Therapeutic Area Head - Cardiovascular & Metabolism R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
03.2009 - 05.2011
- Reporting to the Global Head of Pharmaceutical R&D, responsible for global 'end to end' research and development for all pharmaceutical therapeutics for the treatment of cardiovascular and metabolic (CVM) diseases, predominantly in Diabetes, Obesity & Thrombosis
- Led global team of clinical and preclinical scientists including physicians, pharmacologists, biologists and medicinal chemists
- Responsible for the development of INVOKANA for type 2 Diabetes and XARELTO (in partnership with Bayer Pharma) for multiple indications in arterial and venous thrombosis
- Managed early portfolio for multiple metabolic indications including obesity & type 2 diabetes.
Vice President Global Clinical Development - Internal Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson
10.2008 - 03.2009
- Reporting to the Global President of CNS/IM R&D, worldwide responsibility for the development of pharmaceutical therapeutics in Metabolism, Womens' Health and Anti-Infectives.
Vice President Global Clinical Development & Medical Affairs - Cardiovascular & Metabolism
Novartis
05.2006 - 10.2008
- Responsible for global development and medical affairs activities for GALVUS, a novel DPP-IV inhibitor for the treatment of type 2 diabetes
- Including global pivotal registrations (studies and filing), fixed dose combination development, phase 3B/4 studies.
Vice President US Medical Affairs
Sanofi-Aventis U.S. LLC
05.2005 - 05.2006
- Responsible for the cardiometabolic & obesity (rimonabant) therapeutic area within US Medical Affairs, reporting to the US Chief Medical Officer
- Directed US medical strategy for rimonabant in the US including phase 4 and investigator sponsored studies, national medical education, publications, marketing support.
Senior Director, Vice President, Global Clinical Development - Internal Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson
01.2000 - 04.2005
- Encompassed global clinical development of products in the Metabolic Diseases (predominantly obesity & type 2 diabetes), Reproductive Health and Gastroenterology.
Director UK Medical Affairs
SmithKline Beecham Corporation
10.1997 - 11.1999
Director Global Clinical Development
Knoll
11.1995 - 10.1997
NHS Surgical Training Rotation - Senior & Junior House Officer
NHS England
08.1991 - 11.1995
Education
FRCS - Fellow of the Royal College of Surgeons -
The Royal College of Surgeons of London
London, UK01.1995
Bachelor of Medicine and Surgery -
University of Nottingham
Nottingham, UK01.1991
Committees & Board Memberships
The International Federation of Pharmaceutical Manufacturers & Traders (IFPMA): J&J Lead representative on Global Council 2020-2023
The Anti-Microbial Resistance Action Fund (AMRAF): Board Member, representing J&J 2021-2023
Timeline
Global Head, Global Public Health (GPH)
Johnson & Johnson
02.2020 - 04.2023
Global Therapeutic Area Head - Pulmonary Hypertension R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
10.2017 - 02.2020
Global Head, Research & Development - Medical Devices & Orthopedics
Johnson & Johnson MedTech
07.2014 - 10.2017
Chief Operating Officer - Pharmaceuticals R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
05.2011 - 06.2014
Global Therapeutic Area Head - Cardiovascular & Metabolism R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson
03.2009 - 05.2011
Vice President Global Clinical Development - Internal Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson
10.2008 - 03.2009
Vice President Global Clinical Development & Medical Affairs - Cardiovascular & Metabolism
Novartis
05.2006 - 10.2008
Vice President US Medical Affairs
Sanofi-Aventis U.S. LLC
05.2005 - 05.2006
Senior Director, Vice President, Global Clinical Development - Internal Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson
01.2000 - 04.2005
Director UK Medical Affairs
SmithKline Beecham Corporation
10.1997 - 11.1999
Director Global Clinical Development
Knoll
11.1995 - 10.1997
NHS Surgical Training Rotation - Senior & Junior House Officer
NHS England
08.1991 - 11.1995
FRCS - Fellow of the Royal College of Surgeons -
The Royal College of Surgeons of London
Bachelor of Medicine and Surgery -
University of Nottingham
Similar Profiles
Dithma NeedhamDithma Needham
Abiomed Clinical Consultant at Johnson & Johnson, Medical DevicesAbiomed Clinical Consultant at Johnson & Johnson, Medical Devices
Nadim MohamedNadim Mohamed
CAR-T Manufacturing Operator at Johnson & JohnsonCAR-T Manufacturing Operator at Johnson & Johnson
Deja S. NicolasDeja S. Nicolas
VSAP Overlay Representative – Oncology & Urology at Johnson & Johnson Innovative MedicineVSAP Overlay Representative – Oncology & Urology at Johnson & Johnson Innovative Medicine